Gossamer Bio, Inc. (NasdaqGS: GOSS)
Health Care · Biotechnology · US
$0.20
+16.86% today · -92.6% 1Y
Gossamer Bio, Inc. (NasdaqGS: GOSS) operates in the Biotechnology industry within the Health Care sector. The company is valued at $85.55M and employs 162 people.
Over the last twelve months the share price has lost 92.6%, trading between 0.11 and 3.87.
Tweenvest scores Gossamer Bio, Inc. across four factors: quality 30/100, value 51/100. Its strongest factor is value.
GOSS price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $85.55M
- Revenue (TTM)
- $53.29M
- P/E
- —
- EPS
- -0.65
- Dividend yield
- —
- Beta (5Y)
- 2.01
- 52-week high
- $3.87
- 52-week low
- $0.11
- Avg volume (3M)
- —
- Shares outstanding
- 488.85M
- Employees
- 162
- Next earnings
- —
About Gossamer Bio, Inc.
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
- ISIN
- US38341P1021
- Founded
- 2015
- Listed since
- Feb 8, 2019
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $63.06B | €879.20 | +1.74% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $158.83 | +14.36% |
Figures last refreshed Aug 18, 2026.